(NASDAQ: RGEN) Repligen's forecast annual revenue growth rate of 13.33% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 7.67%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.61%.
Repligen's revenue in 2026 is $805,610,000.On average, 24 Wall Street analysts forecast RGEN's revenue for 2026 to be $54,098,020,232, with the lowest RGEN revenue forecast at $51,275,147,962, and the highest RGEN revenue forecast at $57,454,655,714. On average, 22 Wall Street analysts forecast RGEN's revenue for 2027 to be $64,371,204,166, with the lowest RGEN revenue forecast at $58,385,385,340, and the highest RGEN revenue forecast at $73,320,527,486.
In 2028, RGEN is forecast to generate $75,046,468,412 in revenue, with the lowest revenue forecast at $66,416,763,782 and the highest revenue forecast at $84,890,724,064.